Safety and efficacy of anticoagulation therapy with low molecular weight heparin for portal vein thrombosis in patients with liver cirrhosis.
J Clin Gastroenterol
; 44(6): 448-51, 2010 Jul.
Article
en En
| MEDLINE
| ID: mdl-19730112
ABSTRACT
BACKGROUND:
Treatment of portal vein thrombosis (PVT) in patients with liver cirrhosis is not well established.AIM:
We intended to assess the safety and efficacy of low molecular weight heparin (LMWH) to treat PVT in cirrhotic patients. STUDY All 39 patients diagnosed with non-neoplastic PVT and cirrhosis from June 2005 to December 2006 were evaluated for anticoagulation therapy (AT). PVT was occludent in 15.4%, partial in 64.1%, and portal cavernoma presented in 20.5%. Twenty-eight patients received 200 U/kg/d of enoxaparin for at least 6 months. In 39.3% of patients PVT was an occasional finding, in 10.7% presented with acute abdominal pain, in 50% with bleeding from gastroesophageal varices. In this last group LMWH was started after endoscopic eradication of varices by band ligation.RESULTS:
Complete recanalization of portal vein occurred in 33.3%, partial recanalization in 50% and no response in 16.7% of patients. Further 12 patients who continued AT obtained complete recanalization at a median time of 11 months (range 7 to 17 mo). Overall, a complete response was obtained in 75% of patients. No significant side effects, particularly bleeding complications, were observed during the treatment.CONCLUSIONS:
LMWH demonstrated safe and effective in the treatment of PVT in patients with liver cirrhosis.
Texto completo:
1
Base de datos:
MEDLINE
Asunto principal:
Vena Porta
/
Heparina de Bajo-Peso-Molecular
/
Trombosis de la Vena
/
Cirrosis Hepática
/
Anticoagulantes
Tipo de estudio:
Etiology_studies
Idioma:
En
Revista:
J Clin Gastroenterol
Año:
2010
Tipo del documento:
Article